Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JUNIOR STRENGTH MOTRIN vs ACTIQ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.
Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.
FDA-approved for relief of mild to moderate pain,fever reduction,off-label uses include migraine and dysmenorrhea
Management of breakthrough pain in cancer patients aged 16 and older who are already receiving and tolerant to opioid therapy for their underlying persistent cancer pain
200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.
200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.
1.5-2 hours in children; prolonged in neonates (up to 30 hours) and renal impairment. Clinical: short half-life requires frequent dosing for sustained antipyresis/analgesia.
Terminal half-life 0.83–2 hours (mean 1.3 h) in adults; note that context: transmucosal absorption leads to rapid onset but short duration; half-life is not correlated with clinical effect due to oral transmucosal route and rapid redistribution.
Primarily hepatic via CYP2C9, with minor contributions from CYP2C8 and glucuronidation.
Primarily hepatic via CYP3A4 to inactive metabolites (norfentanyl, despropionylfentanyl, hydroxyfentanyl) and other metabolites; <7% excreted unchanged in urine.
Renal excretion of inactive metabolites and conjugates (>90%); less than 10% excreted unchanged. Fecal elimination minor (<5%).
Primarily renal as metabolites (about 75% as metabolites, <10% unchanged). Fecal excretion accounts for <9%. Biliary excretion is minor.
99% bound to albumin.
Fentanyl is 80–85% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
0.2 L/kg in children; low Vd indicates limited tissue distribution and high plasma protein binding. Clinical: mainly confined to vascular compartment.
Approximately 4 L/kg (range 3–6 L/kg); large Vd indicates extensive tissue distribution and redistribution contributing to short duration.
Oral: 80-100% (rapid absorption); rectal: approximately 70-80%.
Oral transmucosal: 50% (range 47–54%) relative to IV; variable and enhanced by rapid absorption through buccal mucosa.
GFR 30-59 m L/min: reduce dose by 50% or avoid; GFR <30 m L/min: contraindicated.
No specific GFR-based dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min) and consider dose reduction due to potential accumulation.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: avoid use.
Child-Pugh Class A/B: No adjustment. Child-Pugh Class C: Reduce initial dose to 100 mcg and titrate slowly; monitor closely for prolonged effects.
6 months to 12 years: 5-10 mg/kg per dose orally every 6-8 hours; maximum 40 mg/kg/day.
Not approved for pediatric use; safety and efficacy not established in patients under 16 years.
Initiate at lowest effective dose; consider renal function; increase dosing interval to every 6-8 hours.
Initiate at 100 mcg transmucosally; titrate slowly due to increased sensitivity and risk of respiratory depression. Monitor for adverse effects.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. NSAIDs are contraindicated for the treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Risk of respiratory depression, addiction, abuse, and misuse; accidental ingestion can be fatal; concomitant use with benzodiazepines or CNS depressants may cause profound sedation, respiratory depression, coma, and death; not for use in opioid non-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; serious, life-threatening, or fatal respiratory depression may occur even at recommended doses.
Risk of GI ulceration, bleeding, and perforation; increased cardiovascular thrombotic events; hypertension; fluid retention and edema; severe skin reactions (e.g., Stevens-Johnson syndrome); renal toxicity, especially in patients with impaired renal function; anaphylactoid reactions.
Risk of respiratory depression; addiction, abuse, and misuse; interactions with CNS depressants; serotonin syndrome; adrenal insufficiency; severe hypotension; seizures; withdrawal; use in patients with head injuries, increased intracranial pressure, biliary tract disease, pancreatitis; risk of choking with lozenge; oral mucosal irritation; dental caries; hypokalemia; hyponatremia; use in elderly, cachectic, or debilitated patients.
Hypersensitivity to ibuprofen or any NSAID; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; perioperative pain in CABG surgery; severe renal impairment; history of GI bleeding or perforation related to NSAIDs.
Significant respiratory depression; acute or severe bronchial asthma in an unmonitored setting or without resuscitative equipment; known or suspected paralytic ileus; hypersensitivity to fentanyl or any component; opioid non-tolerant patients; management of acute or postoperative pain including headache/migraine, dental pain, or emergency department use.
Take with food or milk to minimize gastrointestinal irritation. Avoid alcohol while taking this medication as it increases risk of stomach bleeding.
No significant food interactions. Grapefruit juice may increase fentanyl levels, but specific studies with ACTIQ are lacking. Avoid alcohol, as it may increase sedation and respiratory depression risk.
First trimester: Increased risk of miscarriage and congenital malformations (cardiac, gastroschisis) with NSAID use; a causal relationship has not been firmly established. Second trimester: Generally considered lower risk, but avoid prolonged use. Third trimester: Known association with premature closure of the ductus arteriosus, oligohydramnios, and fetal renal dysfunction; contraindicated after 30 weeks gestation.
FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause neonatal opioid withdrawal syndrome; avoid use during labor due to risk of neonatal respiratory depression.
Ibuprofen is excreted into breast milk in very low amounts (M/P ratio approximately 0.01-0.02). Peak milk concentration occurs 1-2 hours after maternal dose. Due to the low concentration and short half-life in infants, ibuprofen is considered compatible with breastfeeding when used at recommended doses for short durations.
Excreted in breast milk; M/P ratio not established. Limited data suggest low levels, but risk of infant sedation and respiratory depression. Avoid use while breastfeeding unless potential benefit outweighs risk.
No specific dose adjustment is recommended in pregnancy for occasional use. However, due to pharmacokinetic changes (increased volume of distribution and clearance), lower doses may be less effective; use the lowest effective dose for the shortest duration. Avoid routine use after 20 weeks due to fetal risks.
Due to increased plasma volume and hepatic metabolism in pregnancy, dose requirements may increase; adjust based on clinical response and tolerance. Avoid use during labor and delivery due to risk of neonatal respiratory depression; short-term use preferred.
For pediatric patients, use weight-based dosing (5-10 mg/kg/dose) rather than age-based to ensure efficacy and safety. Limit to 4 doses per day; maximum 40 mg/kg/day or 1.2 g/day, whichever is less. Do not combine with other NSAIDs. Use lowest effective dose for shortest duration. Contraindicated in children with active peptic ulcer disease, severe renal impairment, or known hypersensitivity to ibuprofen or aspirin.
ACTIQ is a transmucosal immediate-release fentanyl formulation indicated for breakthrough cancer pain in opioid-tolerant patients. Initiate with the lowest strength (200 mcg) and titrate upward. Avoid use in opioid-naive patients due to risk of fatal respiratory depression. Place the unit between cheek and lower gum, not sublingually. Instruct patient not to bite or suck the unit. Monitor for sedation and respiratory depression. Multiple units may be used per episode if needed, but wait at least 4 hours before next episode. Dispose of partially used units by flushing down toilet.
Give with food or milk to reduce stomach upset.,Use weight-based dosing: shake suspension well before use; use dosing syringe or cup provided.,Do not exceed 4 doses in 24 hours; wait at least 4 hours between doses.,Do not give with other pain relievers containing ibuprofen, naproxen, or aspirin.,Stop use and consult doctor if pain worsens or lasts more than 10 days, or if fever lasts more than 3 days.,Seek medical help immediately if signs of allergic reaction (rash, hives, swelling, trouble breathing) or stomach bleeding (bloody or black stools, vomit that looks like coffee grounds) occur.
Only use ACTIQ if you are already taking regular around-the-clock opioid pain medicine and are tolerant to opioids.,Do not use ACTIQ for short-term pain like after surgery, headache, or dental pain.,Place the unit in your cheek pouch, not under your tongue. Do not chew or suck it.,If you need more than 4 units per day, contact your doctor as your dose may need adjustment.,Store ACTIQ in a safe place away from children, as accidental ingestion can be fatal.,Dispose of unused or partially used units by flushing them down the toilet.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JUNIOR STRENGTH MOTRIN vs ACTIQ, answered by our medical review team.
JUNIOR STRENGTH MOTRIN is a NSAID Analgesic that works by Cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, thereby decreasing inflammation, pain, and fever.. ACTIQ is a Opioid Analgesic that works by Opioid agonist; binds to mu-opioid receptors in the CNS, altering pain perception and response.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JUNIOR STRENGTH MOTRIN and ACTIQ depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JUNIOR STRENGTH MOTRIN is: 200-400 mg orally every 4-6 hours as needed; maximum 1200 mg/day without prescription.. The standard adult dose of ACTIQ is: 200 mcg transmucosally, titrated upward as needed; initial dose for opioid-tolerant patients is 200 mcg, with additional doses possible after 15 minutes if needed. Maximum 4 doses per episode. At least 4 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JUNIOR STRENGTH MOTRIN and ACTIQ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JUNIOR STRENGTH MOTRIN is classified as Category C. First trimester: Increased risk of miscarriage and congenital malformations (cardiac, gastroschisis) with NSAID use; a causal relationship has not been firmly established. Second t. ACTIQ is classified as Category C. FDA Pregnancy Category C. First trimester: limited human data; animal studies show increased resorptions and fetal growth restriction. Second/third trimester: chronic use may cause. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.